Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials.
about
Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.Efficacy and safety of angiogenesis inhibitors in small-cell lung cancerClinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer.Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.
P2860
Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Angiogenesis inhibitors rechal ...... randomized controlled trials.
@en
type
label
Angiogenesis inhibitors rechal ...... randomized controlled trials.
@en
prefLabel
Angiogenesis inhibitors rechal ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Angiogenesis inhibitors rechal ...... randomized controlled trials.
@en
P2093
P2860
P304
P356
10.2147/OTT.S88102
P407
P50
P577
2015-10-03T00:00:00Z